MFG Wealth Management Inc. Buys Shares of 20,239 DexCom, Inc. (NASDAQ:DXCM)

MFG Wealth Management Inc. acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 20,239 shares of the medical device company's stock, valued at approximately $1,574,000.

Other hedge funds have also recently modified their holdings of the company. Versant Capital Management Inc bought a new stake in shares of DexCom during the 4th quarter valued at $25,000. Riverview Trust Co grew its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after acquiring an additional 232 shares during the period. Heck Capital Advisors LLC bought a new stake in shares of DexCom during the 4th quarter valued at $38,000. MassMutual Private Wealth & Trust FSB grew its position in shares of DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company's stock valued at $65,000 after acquiring an additional 265 shares during the period. Finally, RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom during the 3rd quarter valued at $57,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an "outperform" rating on the stock in a research note on Friday, October 25th. JPMorgan Chase & Co. lifted their target price on shares of DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Finally, Canaccord Genuity Group lifted their target price on shares of DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Friday. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $99.06.

Remove Ads

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the company's stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the company's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,342 shares of company stock worth $3,628,069. Insiders own 0.30% of the company's stock.

DexCom Price Performance

Shares of DexCom stock traded up $4.98 during trading hours on Friday, reaching $89.07. The company's stock had a trading volume of 7,591,102 shares, compared to its average volume of 3,361,682. The firm has a 50 day moving average price of $82.44 and a 200-day moving average price of $75.44. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The stock has a market cap of $34.79 billion, a P/E ratio of 53.34, a P/E/G ratio of 2.26 and a beta of 1.14.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, analysts predict that DexCom, Inc. will post 1.69 EPS for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.